Using ultrasound to predict kidney outcomes in sepsis patients
Venous Excess Ultrasound Score (VExUS) Combined With Central Venous Pressure (CVP) to Predict Clinical Outcomes in Sepsis Participants
The Second People's Hospital of Yibin · NCT06524622
This study is testing if using ultrasound to measure blood flow can help doctors predict kidney problems in sepsis patients in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | The Second People's Hospital of Yibin (other) |
| Locations | 1 site (Yibin, Sichuan) |
| Trial ID | NCT06524622 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between the Venous Excess Ultrasound Score (VExUS) and Central Venous Pressure (CVP) in patients with sepsis admitted to the ICU. By measuring venous congestion through ultrasound and monitoring CVP during the first three days of ICU admission, the study aims to predict major adverse kidney events within 30 days. The primary outcome focuses on the association between these two measures and the risk of acute kidney injury and mortality. The study will enroll adult participants from multiple hospitals in Sichuan, China, between July 2024 and January 2025.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are diagnosed with sepsis upon ICU admission.
Not a fit: Patients under 18, those with severe renal impairment, or those receiving palliative care may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the prediction and management of kidney complications in sepsis patients, potentially reducing morbidity and mortality.
How similar studies have performed: While the use of ultrasound in assessing venous congestion is gaining traction, this specific combination of VExUS and CVP in sepsis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult participants (age ≥ 18 years) with sepsis upon admission or during their stay in the ICU. Exclusion Criteria: * Age \< 18 years * Participants admitted to the ICU for \< 24 hours * Pregnant or lactating women * Severe renal impairment (defined as baseline estimated glomerular filtration rate \< 15 mL/min or requiring regular dialysis), including causes such as urinary tract obstruction, contrast agents, or nephrotoxic drugs * Liver cirrhosis with portal hypertension * Presence of urinary tract obstruction (which may affect IRVF waveform) * Inability to resolve the primary disease * Participants receiving palliative care * Inability to obtain ultrasound images * Inability to monitor CVP * Refusal of monitoring by participants or their families
Where this trial is running
Yibin, Sichuan
- Point-of-care ultrasound (POCUS) — Yibin, Sichuan, China (RECRUITING)
Study contacts
- Principal investigator: lianghai cao, Master's — Yibin Second People's Hospital, Associate Chief Physician
- Study coordinator: xueqian wang
- Email: 18380722724@163.com
- Phone: 18380722724
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, Acute Kidney Injury, VExUS, CVP, acute kidney injury, MAKE30, venous congestion